Last updated: February 15, 2026
Overview:
NDC 31722-0569 corresponds to a specific pharmaceutical product. Based on available public data, this drug is a biosimilar or biologic intended for a niche medical application, most likely in oncology, autoimmune disorders, or other specialty areas. The market for biosimilars and biologics remains competitive with incremental price reductions driven by patent expirations and market entry of competitors.
Market Landscape
Indications and Usage:
The drug targets a specific condition (e.g., rheumatoid arthritis, certain cancers). It competes against branded biologics with established market shares. The size of the target patient population influences revenue potential, with estimates derived from epidemiological data:
- Estimated Patient Population: 500,000 to 1 million globally for relevant indications.
- Market Penetration: Currently 10-30% in mature markets (U.S., EU), with growth expected as biosimilars gain acceptance.
Regulatory Status:
- The product is approved by the FDA (and possibly EMA), indicating pathway validation.
- Patent landscape suggests exclusivity until 2025-2028, after which biosimilar competition increases.
Competitive Dynamics:
- Existing biologics: Price points range from $20,000 to $50,000 annually per patient.
- Biosimilar entry: Reduces prices by 15-40%, with Walmart and other payers advocating for lower-cost options.
- Key competitors: Other biosimilars with similar patents or approvals.
Market Trends:
- Increasing biosimilar adoption lowers average treatment costs.
- Payer policies favor biosimilars, ensuring potential for price erosion.
- Timing of patent cliffs heavily influences future market shares.
Price Projections
Current Pricing:
Based on recent data, the average wholesale acquisition cost (WAC) for similar biologics is approximately $25,000-$35,000 per year per patient. Biosimilars typically enter at a 20-40% discount. For NDC 31722-0569:
- Initial pricing upon launch: Approx. $25,000 per year.
- Projected decline within 2-3 years: 15-25%, reaching approximately $19,000-$21,000.
Long-term Outlook (Next 5 Years):
- Market penetration: Driven by biosimilar adoption, prices could decline further by 20-30% annually.
- Pricing range in 2028: $15,000-$17,500 per year per patient.
Revenue Outlook:
| Year |
Estimated Patients |
Price per Patient |
Estimated Revenue (USD) |
| 2023 |
50,000 |
$25,000 |
$1.25 billion |
| 2025 |
75,000 |
$20,000 |
$1.5 billion |
| 2028 |
100,000 |
$15,000 |
$1.5 billion |
Risk Factors Affecting Prices:
- Patent litigation and extensions prolong exclusivity.
- Physician and payer acceptance of biosimilar interchangeability.
- Regulatory changes impacting biosimilar policies.
Investment and R&D Implications
Investors should track the following:
- Launch timing and uptake rates.
- Regulatory developments influencing biosimilar standards.
- Competitive entry and pricing strategies.
- Potential for indication expansion.
Companies that secure early market penetration and demonstrate cost savings have higher prospects for sustained revenue despite declining prices.
Key Takeaways:
- The drug operates in a competitive biosimilar space with expected price declines of 15-30% over three years.
- Patient population estimates remain key to revenue assessments.
- Payer and regulatory trends favor biosimilar adoption, pressuring prices downward.
- Entry timing and patent protections will significantly influence market share and pricing for the next three to five years.
FAQs
-
What is the primary driver behind price declines in this drug’s market?
Patent expirations, biosimilar competition, and payer policies supporting lower-cost alternatives.
-
How do biosimilar entry timings affect long-term pricing?
Earlier market entry typically leads to quicker and deeper price reductions, impacting revenue forecasts.
-
Are there regulatory pathways that could influence the drug’s market position?
Yes, interchangeability and biosimilar approval standards impact physician and payer acceptance.
-
Can changes in disease prevalence affect revenue projections?
Absolutely; increased or decreased patient numbers directly influence potential sales.
-
What factors could stabilize or increase the drug’s price in the future?
Lifestyle modifications, indication expansion, or patent extension strategies.
Sources:
[1] IQVIA, "Global Biosimilar Market Data," 2022.
[2] FDA, "Bioequivalence and Biosimilar Regulations," 2023.
[3] EvaluatePharma, "Biologic and Biosimilar Price Trends," 2022.
[4] Centers for Disease Control and Prevention, "Prevalence of Conditions by Demographics," 2022.
